Market News & Trends
Xcelience Opens New Development Facility
Xcelience LLC recently announced the grand opening of a new 24,000-sq-ft facility, located south of the Tampa airport at 4901 Grace Street. The building will…
Cobra Biologics & Algeta Sign Monoclonal Antibody Agreement
Cobra Biologics Ltd and Algeta ASA recently announced a new contract manufacturing partnership for Algeta's fourth Targeted Thorium Conjugate (TTC) program. The program will focus…
Growth Predicted for the European Vaccines Market
As vaccine manufacturers increasingly tend to leverage on novel technologies, and potential late-stage vaccine candidates progress the pipeline and reach the commercialization stage, the European…
InSite Vision Introduces DuraSite 2
InSite Vision Incorporated recently introduced DuraSite 2, its next-generation enhanced drug delivery system that provides a broad platform for developing superior ophthalmic therapeutics. DuraSite 2…
Quotient & Pulmatrix Announce Completion of Innovative Program
Quotient Clinical and Pulmatrix recently announced the completion of an early clinical program to achieve proof-of-concept data in COPD patients for PUR118, Pulmatrix's lead iCALM…
Third Critically Ill Patient Successfully Treated With PLX Cells Under Compassionate Use
Pluristem Therapeutics, Inc. recently announced the company's Placental eXpanded (PLX) cells were successfully administered to a third patient in Hadassah Medical Center; thus, a series…
West Announces Self-Injection Technology Agreement
West recently announced an agreement with Janssen Biotech, Inc. to collaborate on the development and manufacturing of an innovative self-injection product. The technology, developed by…
9/12/2012
Cobra Biologics & Algeta Sign Monoclonal Antibody Agreement Cobra Biologics Ltd and Algeta ASA recently announced a new contract manufacturing partnership for Algeta's fourth Targeted…
9/5/2012
Genmab Signs Potential Billion Dollar Agreement Genmab recently announced a global license and development agreement for daratumumab (HuMax-CD38), a human CD38 monoclonal antibody with Janssen…
Charles River Buys Company for $17 Million
Charles River Laboratories International, Inc. recently announced it has acquired Accugenix, Inc., the premier global provider of cGMP-compliant contract microbial identification testing, for approximately $17…
Genmab Signs Potential Billion Dollar Agreement
Genmab recently announced a global license and development agreement for daratumumab (HuMax-CD38), a human CD38 monoclonal antibody with Janssen Biotech, Inc., one of the Janssen…
Hovione Announces New Director
Hovione recently announced the appointment of Dr. Conrad Winters as Director, Drug Product Development. Dr. Winters was previously with Merck in US and Canada and…
SeraCare Expands HCV & HTLV Performance Panel Offerings
SeraCare Life Sciences recently announced it has expanded its performance panel product offerings. SeraCare's third Worldwide HCV RNA Performance Panel and eighth Anti-HTLV I/II Mixed…
Sunovion to Buy Company in Deal Worth $430 Million
Sunovion Pharmaceuticals Inc. recently announced it has signed a definitive agreement to acquire Elevation Pharmaceuticals, Inc. The acquisition includes Elevation Pharmaceuticals' EP-101 product, an inhalation…
Thermo Fisher Announces New Method
Thermo Fisher Scientific recently announced a new method that can automatically extract glycoproteins from samples, and glycopeptides from tryptic digests, thus enabling faster isolation, better…
DPT Laboratories Names New VP & GM of Center of Excellence
DPT Laboratories recently announced that Gene Ciolfi has been promoted to Vice President and General Manager, Site Operations, DPT Lakewood, NJ. Mr. Ciolfi, who joined…
ImmunoGen Announces Significant Phase III Study Results
ImmunoGen, Inc. recently announced that Roche has reported that updated results from its EMILIA Phase III trial show that patients treated with trastuzumab emtansine had a…
Pyramid Laboratories Expands cGMP Services
Pyramid Laboratories, Inc. a premier clinical and commercial parenteral manufacturer, recently announced it has expanded its portfolio of services with the addition of a new…
Synergy Pharmaceuticals Acquires BMS Drug
Synergy Pharmaceuticals Inc. recently announced it has signed an Asset Purchase Agreement with Bristol-Myers Squibb Company and has acquired the assets related to FV-100, an…
8/29/2012
Synergy Pharmaceuticals Acquires BMS Drug Synergy Pharmaceuticals Inc. recently announced it has signed an Asset Purchase Agreement with Bristol-Myers Squibb Company and has acquired the…
